Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Euronext Bruxelles  >  Ablynx    ABLX   BE0003877942

ABLYNX (ABLX)
Mes dernières consult.
Most popular
Report
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
 News SummaryMost relevantAll newsSector newsTweets
Most relevant news about ABLYNX
11/16 ABLYNX : 16/11/2017 ablynx announces results for the first nine months of 2017 a..
11/16 ABLYNX : Announces results for the first nine months of 2017 and a year-to-date ..
11/15 ABLYNX : 15/11/2017 publication in accordance with article 14 of the belgian law..
11/15 ABLYNX : Publication in accordance with article 14 of the belgian law of 2 may 2..
11/15 ABLYNX : Publication in accordance with article 14 of the belgian law of 2 may 2..
11/15 ABLYNX : Publication in accordance with article 14 of the belgian law of 2 may 2..
11/13ABLYNX NV : quaterly earnings release
11/10 ABLYNX : 10/11/2017 publication in accordance with article 14 of the belgian law..
11/10 ABLYNX : Publication in accordance with article 14 of the belgian law of 2 may 2..
11/09 ABLYNX : 09/11/2017 ablynx to present at upcoming investor conferences in london..
11/09 ABLYNX : To present at upcoming investor conferences in london and paris
11/07 ABLYNX : 07/11/2017 publication in accordance with article 14 of the belgian law..
11/07 ABLYNX : Publication in accordance with article 14 of the belgian law of 2 may 2..
11/07 ABLYNX : 07/11/2017 correction of publication in accordance with article 14 of t..
11/07 ABLYNX : Publication in accordance with article 14 of the belgian law of 2 may 2..
More most relevant news
All news about ABLYNX
11/16 ABLYNX : 16/11/2017 ablynx announces results for the first nine months of 2017 a..
11/16 ABLYNX : Announces results for the first nine months of 2017 and a year-to-date ..
11/15 ABLYNX : 15/11/2017 publication in accordance with article 14 of the belgian law..
11/15 ABLYNX : Publication in accordance with article 14 of the belgian law of 2 may 2..
11/15 ABLYNX : Publication in accordance with article 14 of the belgian law of 2 may 2..
11/15 ABLYNX : Publication in accordance with article 14 of the belgian law of 2 may 2..
11/13ABLYNX NV : quaterly earnings release
11/10 ABLYNX : 10/11/2017 publication in accordance with article 14 of the belgian law..
11/10 ABLYNX : Publication in accordance with article 14 of the belgian law of 2 may 2..
11/09 ABLYNX : 09/11/2017 ablynx to present at upcoming investor conferences in london..
More news
Sector news : Biotechnology & Medical Research - NEC
11/16 Recovery rally for European stocks leaves oil sector behind
11/13 Poor earnings updates keep European shares at seven-week low
11/13DJNOVARTIS : Vision Drug Shows Positive Results in Phase 3 Trials
11/03 Prosecutors search Metro offices in insider trading probe
11/01DJAs Experimental Treatments Grow, Families Face Tough Choices
10/31 Pfizer expects broad interest for consumer health business
More sector news : Biotechnology & Medical Research - NEC
News from SeekingAlpha
11/16 Ablynx NV reports 9M results
10/18 YOUR DAILY PHARMA SCOOP : AZN's Imfinzi SBLA; Ablynx U.S. IPO; Is Teva A Buy?
10/17 Ablynx prices $175M U.S. IPO at $20.95
10/04 3 THINGS IN BIOTECH YOU SHOULD LEARN : October 4, 2017
10/03 YOUR DAILY PHARMA SCOOP : Pfizer A Buy, Our Ablynx Pick Successful, VBLT, DVAX, ..
10/02 Ablynx's caplacizumab successful in late-stage study in rare blood disorder; ..
Financials (€)
Sales 2017 59,0 M
EBIT 2017 -55,7 M
Net income 2017 -75,2 M
Finance 2017 8,18 M
Yield 2017 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales 2017 22,2x
EV / Sales 2018 23,6x
Capitalization 1 315 M
Chart ABLYNX
Duration : Period :
Ablynx Technical Analysis Chart | ABLX | BE0003877942 | 4-Traders
Technical analysis trends ABLYNX
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 5
Average target price 18,4 €
Spread / Average Target 4,7%
EPS Revisions
Managers
NameTitle
Edwin Moses Chief Executive Officer & Executive Director
Peter John Fellner Chairman
Wim Ottevaere Chief Financial Officer
Antonin Rollet de Fougerolles Chief Scientific Officer
Robert K. Zeldin Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
ABLYNX62.74%1 550
CELLTRION, INC.--.--%24 494
INCYTE CORPORATION4.96%22 471
IQVIA HOLDINGS INC36.54%22 070
LONZA GROUP56.09%19 543
ALNYLAM PHARMACEUTICALS, INC.236.40%12 427